Cargando…

Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year

A 73-year-old man with a history of lethargy, fever and dyspnea was admitted to Tottori University Hospital. A computed tomography (CT) scan revealed splenomegaly and diffusely spreading ground-glass opacities (GGOs) in both lungs. A video-assisted thoracoscopic surgery (VATS)-guided lung biopsy rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishii-Ito, Shizuka, Izumi, Hiroki, Touge, Hirokazu, Takeda, Kenichi, Hosoda, Yuzuru, Yamasaki, Akira, Kuwamoto, Satoshi, Shimizu, Eiji, Motokura, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228415/
https://www.ncbi.nlm.nih.gov/pubmed/28105347
http://dx.doi.org/10.3892/mco.2016.1063
_version_ 1782493953482817536
author Nishii-Ito, Shizuka
Izumi, Hiroki
Touge, Hirokazu
Takeda, Kenichi
Hosoda, Yuzuru
Yamasaki, Akira
Kuwamoto, Satoshi
Shimizu, Eiji
Motokura, Toru
author_facet Nishii-Ito, Shizuka
Izumi, Hiroki
Touge, Hirokazu
Takeda, Kenichi
Hosoda, Yuzuru
Yamasaki, Akira
Kuwamoto, Satoshi
Shimizu, Eiji
Motokura, Toru
author_sort Nishii-Ito, Shizuka
collection PubMed
description A 73-year-old man with a history of lethargy, fever and dyspnea was admitted to Tottori University Hospital. A computed tomography (CT) scan revealed splenomegaly and diffusely spreading ground-glass opacities (GGOs) in both lungs. A video-assisted thoracoscopic surgery (VATS)-guided lung biopsy revealed intravascular proliferation of large atypical lymphoid cells in the arteries, veins and alveolar walls. The patient was diagnosed with intravascular large B-cell lymphoma (IVLBCL); he received 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) immunochemotherapy and has remained in complete remission for >1 year. Although IVLBCL is a rare disease, it should be considered in the differential diagnosis of pulmonary diffuse lesions that present with GGOs on CT scans.
format Online
Article
Text
id pubmed-5228415
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-52284152017-01-19 Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year Nishii-Ito, Shizuka Izumi, Hiroki Touge, Hirokazu Takeda, Kenichi Hosoda, Yuzuru Yamasaki, Akira Kuwamoto, Satoshi Shimizu, Eiji Motokura, Toru Mol Clin Oncol Articles A 73-year-old man with a history of lethargy, fever and dyspnea was admitted to Tottori University Hospital. A computed tomography (CT) scan revealed splenomegaly and diffusely spreading ground-glass opacities (GGOs) in both lungs. A video-assisted thoracoscopic surgery (VATS)-guided lung biopsy revealed intravascular proliferation of large atypical lymphoid cells in the arteries, veins and alveolar walls. The patient was diagnosed with intravascular large B-cell lymphoma (IVLBCL); he received 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) immunochemotherapy and has remained in complete remission for >1 year. Although IVLBCL is a rare disease, it should be considered in the differential diagnosis of pulmonary diffuse lesions that present with GGOs on CT scans. D.A. Spandidos 2016-12 2016-10-26 /pmc/articles/PMC5228415/ /pubmed/28105347 http://dx.doi.org/10.3892/mco.2016.1063 Text en Copyright: © Nishii-Ito et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Nishii-Ito, Shizuka
Izumi, Hiroki
Touge, Hirokazu
Takeda, Kenichi
Hosoda, Yuzuru
Yamasaki, Akira
Kuwamoto, Satoshi
Shimizu, Eiji
Motokura, Toru
Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
title Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
title_full Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
title_fullStr Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
title_full_unstemmed Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
title_short Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
title_sort pulmonary intravascular large b-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: report of a patient surviving for over 1 year
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228415/
https://www.ncbi.nlm.nih.gov/pubmed/28105347
http://dx.doi.org/10.3892/mco.2016.1063
work_keys_str_mv AT nishiiitoshizuka pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT izumihiroki pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT tougehirokazu pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT takedakenichi pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT hosodayuzuru pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT yamasakiakira pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT kuwamotosatoshi pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT shimizueiji pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year
AT motokuratoru pulmonaryintravascularlargebcelllymphomasuccessfullytreatedwithrituximabcyclophosphamidevincristinedoxorubicinandprednisoloneimmunochemotherapyreportofapatientsurvivingforover1year